ArticleJournal of computer-aided molecular design2026
A novel framework for the discovery of MAPK-activated protein kinase 2 (MAPKAPK2) inhibitors using a multi-feature deep learning ensemble.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MAPKAPK2 is a promising therapeutic target in numerous diseases. However, many MAPKAPK2 inhibitors are plagued by low solubility and permeability, and none have advanced through clinical trials. New computational methods utilizing deep learning can speed up inhibitor identification. This study aims to develop and validate a novel framework for MAPKAPK2 inhibitor discovery utilizing an ensemble of ten individual models trained on various feature sets. We trained DNN models using 21 molecular featurizers and 28 layer-size settings, and selected ten high-performing feature-architecture combinations to establish the ensemble. We explored various voting methods in conjunction with the ensemble and used the ensemble to generate a ranking of potential MAPKAPK2 inhibitors from an in-house compound set. Potential inhibitors satisfying Lipinski and Veber Rules not containing PAINS structures were selected for enzyme assay testing, and a molecular docking simulation was performed to investigate interactions. The individual model with the highest evaluation metrics was trained on functional-class fingerprints. Meanwhile, the ten-model voting ensemble reported an accuracy of 0.969 on a testing set. One novel MAPKAPK2 inhibitor, S021-0180, was identified out of seven tested with enzyme assays. The molecular docking simulation revealed critical ligand-residue interactions within the binding site. The novel computational framework was successful in identifying a novel MAPKAPK2 inhibitor as a promising inhibitor for further optimization in future studies. The established ensemble can be used to evaluate more compound sets for novel MAPKAPK2 inhibitors. Moreover, we anticipate that this new framework can be applied to all protein kinases for rapid compound screening.
Indexed as
Identifiers
42700280What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.